logo
logo
MYGN stock ticker logo

Myriad Genetics, Inc.

NASDAQ•MYGN
CEO: Mr. Paul J. Diaz J.D.
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1995-10-06
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
連絡先情報
322 North 2200 West, Salt Lake City, UT, 84116, United States
801-584-3600
www.myriad.com
時価総額
$453.51M
PER (TTM)
-1.2
26.5
配当利回り
--
52週高値
$10.47
52週安値
$3.76
52週レンジ
16%
順位52Top 73.5%
2.9
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$209.80M+0.00%
直近4四半期の推移

EPS

-$0.08+0.00%
直近4四半期の推移

フリーCF

$10.60M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Hereditary Cancer Revenue Growth Hereditary Cancer revenue reached $372.4M, marking a 2% increase driven by 7% volume growth.
Operating Expense Reduction Total operating expenses fell to $963.8M, down 2%, excluding $319.4M goodwill impairment charge.
Cash Position Strengthened Cash and equivalents increased $47.2M to $149.6M, supported by new $200.0M debt facility.
Prenatal Screen Early Access Launched early access for FirstGene Multiple Prenatal Screen in June 2025 via CONNECTOR study.

リスク要因

Continued Net Loss Position Net loss widened to $365.9M in 2025; company expects to continue incurring net losses in future years.
Reimbursement Coverage Uncertainty Revenue harmed if payors fail to provide adequate payment; UnitedHealthcare coverage change impacted Mental Health revenue.
Single Laboratory Interruption Risk Loss or prolonged interruption of the single Salt Lake City facility seriously harms business operations and capacity.
Intellectual Property Protection Failure to protect proprietary technology via patents risks direct competition and potential litigation costs.

見通し

Focus on Cancer Continuum Strategic intent focuses on accelerating growth in CCC market, prioritizing high-growth applications like MRD testing.
FirstGene Commercial Launch FirstGene Multiple Prenatal Screen, a next-generation 4-in-1 assay, expected full commercial launch in 2026.
Laboratory Scalability Improvements Completed transition to next-gen labs to enhance automation, reduce turnaround time, and improve cost efficiency.
AI Prostate Test Launch Advancing AI-enabled prostate cancer diagnostic test development, anticipating commercial launch in first half 2026.

同業比較

売上高 (TTM)

AMN stock ticker logoAMN
$2.73B
-8.5%
EVH stock ticker logoEVH
$1.88B
-26.6%
MYGN stock ticker logoMYGN
$824.50M
-1.6%

粗利益率 (最新四半期)

VIR stock ticker logoVIR
672.1%
-54902.1pp
IOVA stock ticker logoIOVA
215.9%
+65.9pp
DNA stock ticker logoDNA
124.4%
-21.7pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
NRIX$1.35B-5.6-57.5%8.1%
IOVA$1.35B-4.2-54.5%5.3%
VIR$1.32B-3.0-49.3%18.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.3%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月30日
|
EPS:-$0.07
|
売上高:$202.39M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし